This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 24/8/1403    most recent 01.ATV.0000134705.39654.53v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, L. Articles by Clowes, A. W. Search for Related Content PubMed PubMed Citation Articles by Chen, L. Articles by Clowes, A. W. Related Collections Smooth muscle proliferation and differentiation

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:1403.)
© 2004 American Heart Association, Inc.

Vascular Biology

Vasodilator-Stimulated Phosphoprotein Regulates Proliferation and Growth Inhibition by Nitric Oxide in Vascular Smooth Muscle Cells

Lihua Chen; Günter Daum; Kanchan Chitaley; Scott A. Coats; Daniel F. Bowen-Pope; Martin Eigenthaler; Naresh R. Thumati; Ulrich Walter; Alexander W. Clowes

From the Departments of Surgery (L.C., G.D., K.C., A.W.C.) and Pathology (S.A.C., D.F.B.-P.), University of Washington, Seattle; and Institut für Klinische Biochemie und Pathobiochemie (M.E., N.R.T., U.W.), Josef-Schneider-Strasse, Würzburg, Germany.

Correspondence to Lihua Chen, Box 356410, University of Washington, Seattle, WA 98195. E-mail lihua{at}u.washington.edu

Objective— Vasodilator-stimulated phosphoprotein (VASP) was identified as a substrate for cGMP-dependent protein kinase (PKG) and cAMP-dependent protein kinase (PKA). It is preferentially phosphorylated at serine239 by PKG, whereas serine157 is a preferred phosphorylation site for PKA. In addition, serine157 is phosphorylated by PKC in response to serum. We have investigated the effects of VASP and VASP phosphorylation at serine157 and serine239 on smooth muscle cell (SMC) proliferation and nitric oxide (NO)-mediated growth inhibition.

Methods and Results— Aortic SMCs derived from VASP-deficient mice were transduced with retroviral vectors encoding either wild-type VASP or VASP mutants (S157A-VASP and S239A-VASP), in which serine157 and serine239, respectively, were replaced by a nonphosphorylatable amino acid, alanine. Expression of wt-VASP and S239A-VASP significantly increased proliferation, whereas expression of S157A-VASP was inhibitory. Expression of S239A-VASP rendered SMCs less sensitive to growth inhibition by the NO donor, S-nitroso-n-acetylpenicillamine, when compared with cells expressing wt-VASP. Similar effects were observed in cultured rat SMCs in which wt-VASP, S157A-VASP, and S239A-VASP were expressed.

Conclusions— Our data suggest that VASP phosphorylation at serine157 is required for the growth-stimulatory effect of VASP in SMCs, whereas VASP phosphorylation at serine239 is involved in the growth inhibitory effects of NO on SMCs.

This study investigated the effects of VASP and VASP phosphorylation at serine157 and serine239 on smooth muscle cell proliferation and nitric oxide-mediated growth inhibition. Our data suggest that VASP is a modulator of smooth muscle cell growth by integrating positive and negative signals that target different phosphorylation sites of VASP.

Key Words: vasodilator-stimulated phosphoprotein • smooth muscle cell growth • nitric oxide • phosphorylation • cell signaling

This article has been cited by other articles:

				P. M. Benz, C. Blume, S. Seifert, S. Wilhelm, J. Waschke, K. Schuh, F. Gertler, T. Munzel, and T. Renne Differential VASP phosphorylation controls remodeling of the actin cytoskeleton J. Cell Sci., November 1, 2009; 122(21): 3954 - 3965. [Abstract] [Full Text] [PDF]

				S. Miersch, M. G. Espey, R. Chaube, A. Akarca, R. Tweten, S. Ananvoranich, and B. Mutus Plasma Membrane Cholesterol Content Affects Nitric Oxide Diffusion Dynamics and Signaling J. Biol. Chem., July 4, 2008; 283(27): 18513 - 18521. [Abstract] [Full Text] [PDF]

				H. Chen, Y. C. Levine, D. E. Golan, T. Michel, and A. J. Lin Atrial Natriuretic Peptide-initiated cGMP Pathways Regulate Vasodilator-stimulated Phosphoprotein Phosphorylation and Angiogenesis in Vascular Endothelium J. Biol. Chem., February 15, 2008; 283(7): 4439 - 4447. [Abstract] [Full Text] [PDF]

				P. M. Benz, C. Blume, J. Moebius, C. Oschatz, K. Schuh, A. Sickmann, U. Walter, S. M. Feller, and T. Renne Cytoskeleton assembly at endothelial cell cell contacts is regulated by {alpha}II-spectrin VASP complexes J. Cell Biol., January 10, 2008; 180(1): 205 - 219. [Abstract] [Full Text] [PDF]

				X. Wang, J. L. Pluznick, D. C. Settles, and S. C. Sansom Association of VASP with TRPC4 in PKG-mediated inhibition of the store-operated calcium response in mesangial cells Am J Physiol Renal Physiol, December 1, 2007; 293(6): F1768 - F1776. [Abstract] [Full Text] [PDF]

				S. M. Shirvani, L. Mookanamparambil, M. F. Ramoni, and M. T. Chin Transcription factor CHF1/Hey2 regulates the global transcriptional response to platelet-derived growth factor in vascular smooth muscle cells Physiol Genomics, June 19, 2007; 30(1): 61 - 68. [Abstract] [Full Text] [PDF]

				G. Pula, K. Schuh, K. Nakayama, K. I. Nakayama, U. Walter, and A. W. Poole PKC{delta} regulates collagen-induced platelet aggregation through inhibition of VASP-mediated filopodia formation Blood, December 15, 2006; 108(13): 4035 - 4044. [Abstract] [Full Text] [PDF]

				H. Suzuki, K. Eguchi, H. Ohtsu, S. Higuchi, S. Dhobale, G. D. Frank, E. D. Motley, and S. Eguchi Activation of Endothelial Nitric Oxide Synthase by the Angiotensin II Type 1 Receptor Endocrinology, December 1, 2006; 147(12): 5914 - 5920. [Abstract] [Full Text] [PDF]

				A. L. Nestor, G. T. Cicila, S. E. Karol, K. M. Langenderfer, S. L. Hollopeter, and D. C. Allison Linkage analysis of neointimal hyperplasia and vascular wall transformation after balloon angioplasty Physiol Genomics, April 13, 2006; 25(2): 286 - 293. [Abstract] [Full Text] [PDF]

				F. Hofmann, R. Feil, T. Kleppisch, and J. Schlossmann Function of cGMP-Dependent Protein Kinases as Revealed by Gene Deletion Physiol Rev, January 1, 2006; 86(1): 1 - 23. [Abstract] [Full Text] [PDF]

				L Dertsiz, G Ozbilim, Y Kayisli, G A Gokhan, A Demircan, and U A Kayisli Differential expression of VASP in normal lung tissue and lung adenocarcinomas Thorax, July 1, 2005; 60(7): 576 - 581. [Abstract] [Full Text] [PDF]

				J. Wharton, J. W. Strange, G. M. O. Moller, E. J. Growcott, X. Ren, A. P. Franklyn, S. C. Phillips, and M. R. Wilkins Antiproliferative Effects of Phosphodiesterase Type 5 Inhibition in Human Pulmonary Artery Cells Am. J. Respir. Crit. Care Med., July 1, 2005; 172(1): 105 - 113. [Abstract] [Full Text] [PDF]

				B. Hohenstein, L. Kasperek, D.-J. Kobelt, C. Daniel, S. Gambaryan, T. Renne, U. Walter, K. U. Amann, and C. P.M. Hugo Vasodilator-Stimulated Phosphoprotein-Deficient Mice Demonstrate Increased Platelet Activation but Improved Renal Endothelial Preservation and Regeneration in Passive Nephrotoxic Nephritis J. Am. Soc. Nephrol., April 1, 2005; 16(4): 986 - 996. [Abstract] [Full Text] [PDF]

				F. Hofmann The Biology of Cyclic GMP-dependent Protein Kinases J. Biol. Chem., January 7, 2005; 280(1): 1 - 4. [Full Text] [PDF]

				V. O. Melichar, D. Behr-Roussel, U. Zabel, L. O. Uttenthal, J. Rodrigo, A. Rupin, T. J. Verbeuren, A. Kumar H. S., and H. H. H. W. Schmidt Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis PNAS, November 23, 2004; 101(47): 16671 - 16676. [Abstract] [Full Text] [PDF]